Novocure Raises 2026 Revenue Outlook To $736 Million-$743 Million After Record Quarter
The tumor-therapy maker also lifted its adjusted EBITDA outlook to $24 million to $34 million, from $0 million to $15 million.
Novocure, which makes wearable devices that deliver Tumor Treating Fields to fight cancer, raised its 2026 outlook on Thursday after third-quarter revenue of $193.4 million, up 16% from a year earlier and a quarterly record, the company said. Full-year net revenue is now guided to $736 million to $743 million, up from $710 million to $725 million.
Guidance up, loss narrower
Adjusted EBITDA, the company's earnings measure that strips out interest, taxes, depreciation, amortization and share-based pay, is now expected at $24 million to $34 million for the year, versus the earlier $0 million to $15 million. For the quarter it was $15.7 million, against a negative $3.0 million a year ago.
The net loss narrowed to $10.4 million, or $0.09 per share, from $37.3 million, or $0.33 per share. Gross margin rose to 77% from 73%, which the company attributed mainly to higher patient volumes and lower cost per active patient.
The outlook assumes mid-to-high single-digit revenue growth from Optune Gio, $30 million to $34 million combined from Optune Lua and Optune Pax, and quarterly gross margin in the mid-to-high 70s percent.
Patients and products behind the quarter
Novocure ended September with 5,260 active patients worldwide, versus 4,416 a year earlier, a 19% rise. Optune Gio, its brain-cancer device and the biggest revenue source, had 4,729 active patients, up 11%.
The U.S. brought in $111.9 million of revenue, Germany $24.9 million, France $18.7 million and Japan $14.5 million. Other markets added $18.8 million, and $4.4 million came from one-time benefits tied to higher claims approval rates in the U.S. and Germany.
Optune Lua, for lung cancer, and Optune Pax, for pancreatic cancer, together brought in $11.9 million, with $8.2 million from Lua and $3.7 million from Pax. Lua had 255 active patients, up 83%, and Pax had 276. Greater China revenue from the Zai Lab partnership was $4.5 million.
CEO Frank Leonard said the company is "well-positioned to achieve the commercial, clinical and financial goals we set out in January."
Cash, costs and the fourth-quarter calendar
Cash and short-term investments totaled $463.5 million at September 30. Research and clinical spending rose 8% to $58.1 million, mostly on the KEYNOTE D58 trial, while sales and marketing fell 9% to $53.3 million and general and administrative costs fell 5% to $43.6 million.
In October, Japan's health ministry approved Optune Pax for locally advanced pancreatic cancer, and Novocure signed a trial collaboration with Verastem Oncology to test TTFields with chemotherapy and Verastem's investigational KRAS G12D inhibitor VS-7375 in that disease.
Two fourth-quarter milestones are on the company's calendar: an FDA decision on TTFields for brain metastases from non-small cell lung cancer, and completed enrollment in the KEYNOTE D58 glioblastoma trial.
Sources
- 8-K Filing — NovoCure Ltd (NVCR) — SEC EDGAR
- Exhibit nvcr-20260930xpr.htm — NovoCure Ltd 8-K exhibit — SEC EDGAR
- Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance — businesswire.com